OSE IMMUNO chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 1.81
Dividend & YieldN/A€ (N/A)
Beta 1.06
Market capitalization 108.56M
Operating cash flow -5.24M
ESG Scores unknown

Company description

OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. Its products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II clinical trial in patients with advanced solid tumors or lymphomas; OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the treatment of ulcerative colitis, as well as Sjögren's Syndrome; and FR104, which is in Phase I clinical trial for the treatment of rheumatoid arthritis. The company is also developing BI 765063, which is in Phase I clinical trial to treat solid tumors; OSE-230, an agonist antibody against ChemR23 to resolve chronic inflammation; CLEC-1, a therapeutic target in immune-oncology and identified monoclonal antibody antagonists; and BiCKI, a novel bispecific checkpoint inhibitor platform that targets PD-1 to fight primary and secondary resistance mechanisms developed by cancers. OSE Immunotherapeutics SA has collaborations and partnerships with GERCOR, ARCAGY-GINECO, Foundation FoRT, and Nantes University Hospital; and Boehringer Ingelheim, MabSilico, CKD, Servier, Veloxis Pharmaceuticals, and Chong Kun Dang Pharmaceutical Corporation. The company was formerly known as OSE Pharma SA and changed its name to OSE Immunotherapeutics SA in May 2016. OSE Immunotherapeutics SA was founded in 2012 and is headquartered in Nantes, France.

Sector: Healthcare - Industry: Biotechnology

Financial Ratios
Quick Ratio2.64
Working Capital-0.61
Return On Equity-0.35
Debt To Equity0.64
Fixed Asset Ratio0.82
Fixed Interest Cover-19.42

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities
Total Cashflows From Investing Activities -558k 2.38M -504k -827k
Net Borrowings -485k 4.92M 6.15M 14.69M
Total Cash From Financing Activities -592k 4.76M 23.58M 14.96M
Change To Operating Activities -4.59M 8.55M -3.19M 1.02M
Issuance Of Stock 23k 18.63M 18.63M 265k
Net Income 5.49M -4.65M -16.55M -16.85M
Change In Cash -73k 16.27M 3.53M 4.21M
Effect Of Exchange Rate
Total Cash From Operating Activities 1.08M 9.13M -19.55M -9.92M
Depreciation 116k 482k 730k 990k
Change To Account Receivables
Other Cashflows From Financing Activities -63k -163k -1.2M
Change To Netincome 61k 4.75M -532k 3.62M
Capital Expenditures -593k -336k -210k -472k

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 15.03M 21.62M 22.31M 30.49M
Income Before Tax 4.71M -1.46M -19.25M -17.21M
Net Income 5.49M -4.65M -16.55M -16.85M
Selling General Administrative 3.42M 3.85M 4.7M 8.5M
Gross Profit 24.46M 25.95M 10.42M 26.31M
Ebit 4.85M -1.47M -18.99M -16.62M
Operating Income 4.85M -1.47M -18.99M -16.62M
Interest Expense -186k -181k -273k -836k
Income Tax Expense -783k 3.19M -2.69M -364k
Total Revenue 24.46M 25.95M 10.42M 26.31M
Cost Of Revenue
Total Other Income ExpenseNet -140k 7k -258k -589k
Net Income From Continuing Ops 5.49M -4.65M -16.55M -16.85M
Net Income Applicable To Common Shares 5.49M -4.65M -16.55M -16.85M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 15.15M 30.4M 35.61M 53.99M
Total Stockholder Equity 61.75M 58.54M 61.36M 47.89M
Other Current Liabilities 661k 4.83M 1.09M 1.06M
Total Assets 76.9M 88.93M 96.97M 101.88M
Common Stock 2.96M 3M 3.6M 3.71M
Other Current Assets 1.28M 977k 1.05M 1.72M
Retained Earnings 5.49M -4.65M -16.55M -16.85M
Treasury Stock 31.59M 11.69M 8.87M -4.57M
Cash 9.57M 25.84M 29.37M 33.58M
Total Current Liabilities 9.07M 14.33M 14.13M 16.76M
Other Stockholder Equity 31.76M 11.84M 8.97M -4.41M
Property, Plant, and Equipment 904k 2.7M 3.79M 5.44M
Total Current Assets 23.02M 33.06M 39.83M 44.21M
Net Tangible Assets 61.75M 58.54M 61.36M 47.74M
Net Receivables 8.28M 4.46M 6.92M 5.95M
Accounts Payable 6.55M 6.92M 10.29M 9.61M


Insider Transactions

Here are the insider transactions of stock shares related to OSE IMMUNO:

Filer Name Transaction Text Ownership Date Filer Relation Shares
NO DATA

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to OSE IMMUNO. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on OSE IMMUNO

Here is the result of two systematic investment strategies applied to OSE IMMUNO. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on OSE IMMUNO

The following chart shows the equity curve of the two systematic investment strategies applied to OSE IMMUNO:

OSE IMMUNO automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 63.87% on the backtest period.

Performance at glance

Performance

63.87 %

Latent gain

1118.14 €

Invested capital

1750.66 €

Annualized return

15.65 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on OSE IMMUNO

This is the result of two momentum investment strategies applied to OSE IMMUNO. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on OSE IMMUNO

The following chart shows all the entries opened by the momentum investment system on OSE IMMUNO:

OSE IMMUNO momentum entries
  • The first momentum investment strategy would give 98.17% of return on OSE IMMUNO. That represents 5148.49€ of latent gain with 5244.31€ of employed capital.
  • The second momentum investment strategy would give 95.58% of return on OSE IMMUNO. That represents 3345.83€ of latent gain with 3500.57€ of employed capital.
Performance at glance (1Q Momentum)

Performance

98.17 %

Latent gain

5148.49 €

Invested capital

5244.31 €

Annualized return

1.12 %
Performance at glance (2Q Momentum)

Performance

95.58 %

Latent gain

3345.83 €

Invested capital

3500.57 €

Annualized return

26.55 %

Momentum equity curve on OSE IMMUNO

The following chart shows the equity curve of the two momentum strategies applied to OSE IMMUNO:

OSE IMMUNO momentum equity

Note: the dividends potentially given by OSE IMMUNO are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on OSE IMMUNO

The following chart shows the employed capital evolution of the two momentum strategies on OSE IMMUNO since the beginning:

OSE IMMUNO

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250€, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000€.


Buy the dip strategy result on OSE IMMUNO

Buy the dip entry openings on OSE IMMUNO

OSE IMMUNO

The performance achieved by the robo-advisor on OSE IMMUNO is 2.33%. That represents 5.8$ of latent gain with 249.4€ of employed capital. The following chart shows OSE IMMUNO stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of OSE IMMUNO, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

2.33 %

Latent gain

5.8 €

Invested capital

249.4 €

Annualized return

1.12 %

Equity curve of the strategy applied to OSE IMMUNO

The following chart shows the result of the investment strategy applied to OSE IMMUNO:

OSE IMMUNO

Note: the dividends potentially given by OSE IMMUNO are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on OSE IMMUNO

The following chart shows the employed capital evolution since the beginning of the investment strategy on OSE IMMUNO:

OSE IMMUNO

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on OSE IMMUNO

In this section, I will compare the three previous investment strategies applied to OSE IMMUNO.

Equity curve comparison on OSE IMMUNO

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

OSE IMMUNO investment strategy comparison

Employed capital comparison on OSE IMMUNO

OSE IMMUNO investment comparison

Performance comparison on OSE IMMUNO

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 63.87% 1118.14€ 1750.66€ 15.65%
Momentum 1 quarter 98.17% 5148.49€ 5244.31€ 25.57%
Momentum 2 quarters 95.58% 3345.83€ 3500.57€ 26.55%
Non-directional 2.33% 5.8€ 249.4€ 1.12%
Annualized return comparison

Automatic investment

15.65 %

Momentum 1Q

26.55 %

Momentum 2Q

26.55 %

Non-directional

1.12 %

Correlated stocks

Here are the most positively and negatively correlated stocks with OSE IMMUNO:

Positive correlations

Most correlated stocks this year

  • OSE IMMUNO

  • Most correlated stocks last 3 months

  • OSE IMMUNO

  • Negative correlation

    Most negatively correlated stocks this year


    Most negatively correlated stocks last 3 months

  • Brickell Biotech Inc

  • Note: The algorithm computes the probability of correlation between OSE IMMUNO and the other stocks. There may be false positives or some missing correlated stocks. If the price of OSE IMMUNO does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name OSE IMMUNO
    Country France
    City Nantes
    Address 22, boulevard Benoni Goulin
    Phone 33 2 28 29 10 10
    Website www.ose-immuno.com
    FullTime employees 60
    Industry Biotechnology
    Sector Healthcare
    Exchange XPAR
    Ticker OSE.XPAR
    Market www.euronext.com

    OSE IMMUNO ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown